Al-Ali, Hassan; Lemmon, Vance P.; Bixby, John L. published the artcile< Phenotypic screening of small-molecule inhibitors: implications for therapeutic discovery and drug target development in traumatic brain injury>, Category: naphthyridine, the main research area is TBI therapeutic discovery drug target inhibitor phenotypic screening; Axon regeneration; CNS injury; Cell-based assay; Drug discovery; High-content screening; Kinase inhibitor; Primary neurons.
The inability of central nervous system (CNS) neurons to regenerate damaged axons and dendrites following traumatic brain injury (TBI) creates a substantial obstacle for functional recovery. Apoptotic cell death, deposition of scar tissue, and growth-repressive mols. produced by glia further complicate the problem and make it challenging for re-growing axons to extend across injury sites. To date, there are no approved drugs for the treatment of TBI, accentuating the need for relevant leads. Cell-based and organotypic bioassays can better mimic outcomes within the native CNS microenvironment than target-based screening methods and thus should speed the discovery of therapeutic agents that induce axon or dendrite regeneration. Addnl., when used to screen focused chem. libraries such as small-mol. protein kinase inhibitors, these assays can help elucidate mol. mechanisms involved in neurite outgrowth and regeneration as well as identify novel drug targets. Here, we describe a phenotypic cellular (high content) screening assay that utilizes brain-derived primary neurons for screening small-mol. chem. libraries.
Methods in Molecular Biology (New York, NY, United States) published new progress about Antibodies and Immunoglobulins Role: BUU (Biological Use, Unclassified), BIOL (Biological Study), USES (Uses). 1223001-51-1 belongs to class naphthyridine, and the molecular formula is C24H15F3N4O, Category: naphthyridine.
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem